[en] The cardial side effects of the two radioprotective substances are compared. Both of them decrease the heart rate, however, 2-amino-thyazoline increases the incidence of arhythmias as well. (L.E.)

No abstract available

[en] Published in summary form only

[en] Medical intervention should begin within a few hours after contamination of the human body, otherwise it is impossible to influence the deposition of radioisotopes in the organs and tissues. The choice of decorporating drugs is very limited. One of them is DTPA, capable to accelerate the discharge of transition, rare earth and transuranic elements from the body. Various new agents have been developed for this purpose which can bind radioactive strontium in body fluids and tissues. These new pharmaceuticals are reported preliminarily, and the first experimental results are presented. (N.T.)

[en] Published in summary form only

[en] The effects of 8 Gy ⁶⁰Co-irradiation, of AET (280 mg per kg) and of combined treatment on the catecholamine content of the brain, heart and adrenal glands were examined. Irradiation had no effect neither on the noradrenaline- nor on the dopamine content of the brain; the noradrenaline level of the heart decreased during the first 24 hours, followed by a significant increase. In the adrenal glands the adrenaline + noradrenaline content was not influenced, however, the dopamine level increased significantly. AET by itself decreased noradrenaline in the heart and increased dopamine in the adrenal glands. The combined therapy partially prevented the decrease of noradrenaline in the heart, but in other organs it did not influence the effect of irradiation. (L.E.)

[en] To date, there has been no effective therapy to counter incorporated radionuclides of strontium. In an endeavour to solve this problem, we have synthesized and evaluated various N,N'-distributed derivatives of 1,4,10,13-tetraoxa-7,16-diaza-cyclooctadecane (cryptand 2.2) for their ability to mobilize ⁸⁵Sr²⁺. These ligands are water soluble and have a relatively low acute i.v. toxicity, as demonstrated by their evaluation in rat and mouse. The di-sodium-calcium complex and tetra-sodium salt of the cryptand (2.2) dimalonate have exerted a remarkable decorporation effectiveness for ⁸⁵Sr²⁺ in extracellular space. The tetra-potassium salt of the cryptand (2.2) dimalonate has a moderate effect, while no mobilization activity can be detected with the cryptand (2.2) that does not have a side chain substituent. Animals were initially given ⁸⁵SrCl₂ either i.p. or into the lung, then the compounds were administered 30-60 min later using an alternative route. The degree of decorporation achieved a 80-95% of the initial body burden (ibb) compared with the control values of 20-30%. The agents are resorbed easily from the lung, and the radiostrontium deposition in bone was inhibited strongly by a decorporation agent. The success of the treatment, however is dependent upon the speed with which decorporation therapy commences. (Author)